What revenue guidance did Lilly give after Q3 2026?
On October 29, 2026, Eli Lilly raised its full-year 2026 revenue guidance from US$85–87 billion to US$91–92 billion, according to Drugnews’s November 2, 2026 analysis of the Mounjaro and Zepbound maker. This is company guidance for the full year, rather than completed annual sales.
The original article also makes a prediction about the following year. That editorial prediction is separate from this company-issued guidance.